Sanofi Seeks FDA Withdrawal of Diabetes Drug from Fast-Track Review Amid Political Concerns
In a notable move, Sanofi has requested the FDA to withdraw its type 1 diabetes drug from the expedited review process, citing political interference as a key factor.
Editorial Staff
1 min read
Updated 3 days ago
Sanofi has formally asked the FDA to remove its type 1 diabetes drug from the fast-track review program. This decision appears to be influenced by recent actions taken by a political appointee.
The request comes in light of scrutiny surrounding Commissioner Marty Makary's new review process, which has faced criticism for its handling of drug evaluations.
This development raises questions about the impact of political factors on the regulatory process for critical medications.